The major limitations of our study are that (1) our data does not answer the question of how DDX60 regulates MHC-I molecules, (2) we do not have direct evidence to support whether targeting DDX60 can enhance CD8+ T cell-mediated immunotherapies, and (3) the analyzed patient data could have come from CRC patients with different backgrounds (e.g., sex, age, baseline diseases, and pre-treatments), limiting the accuracy of our analysis. This evidence concerns the gene CD8A and colorectal carcinoma.